Placeholder

Brimonidine Tartrate

 

CAS No:
79570-19-7 Categories: , ,
  • # LGM Pharma is a Brimonidine Tartrate CAS# 79570-19-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Brimonidine Tartrate
  • CAS #: 79570-19-7
  • Mode of Action:

    Brimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. The topical gel reduces erythema through direct vasocontriction.

  • Pharmacodynamics:

    Brimonidine significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. It lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.

  • Metabolism:

    Metabolized primarily by the liver.

  • Toxicity:

    Oral LD50 is 50 mg/kg in mice and 100 mg/kg in rats. Common adverse reactions of the topical gel formulation include erythema, flushing, skin burning sensation, and contact dermatitis.

  • IUPAC: 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
  • ATC: D11AX21 — Brimonidine, S01EA05 — Brimonidine
  • PubChem: 2435
  • DrugBank: DB00484 (APRD00034)
  • Formula: C11H10BrN5
  • Molecular Mass: 292.135
  • Synonyms: 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline, Brimonidina, Brimonidine, Brimonidinum, Bromoxidine
  • SMILES: BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
  • AHFS Code: 52:40.04 — Alpha-adrenergic Agonists, 84:92.00 — Misc. Skin and Mucous Membrane Agents
  • InChl: InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
  • Date Modified: 03-12-19
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service